<table>
<thead>
<tr>
<th>Subject Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Abortion, see Sex-selective abortion</td>
<td></td>
</tr>
<tr>
<td>Absorption, sex differences for drugs 474, 475</td>
<td></td>
</tr>
<tr>
<td>Acute coronary syndrome, see Coronary heart disease</td>
<td></td>
</tr>
<tr>
<td>Addison's disease, features and treatment 319</td>
<td></td>
</tr>
<tr>
<td>Adrenal gland</td>
<td></td>
</tr>
<tr>
<td>diseases, see Addison's disease; Congenital adrenal hyperplasia; Pheochromocytoma endocrine hypertension 325</td>
<td></td>
</tr>
<tr>
<td>hormones 317, 318</td>
<td></td>
</tr>
<tr>
<td>tumors 323, 324</td>
<td></td>
</tr>
<tr>
<td>α-Adrenergic receptor</td>
<td></td>
</tr>
<tr>
<td>delayed ejaculation treatment with agonists 455</td>
<td></td>
</tr>
<tr>
<td>therapeutic targeting in benign prostatic hyperplasia 432</td>
<td></td>
</tr>
<tr>
<td>Adrenocorticotropic hormone, see Cushing's disease</td>
<td></td>
</tr>
<tr>
<td>Adverse drug reactions (ADRs), sex differences 473, 474, 477, 478</td>
<td></td>
</tr>
<tr>
<td>Aggression, see Violence against women</td>
<td></td>
</tr>
<tr>
<td>Aging</td>
<td></td>
</tr>
<tr>
<td>allostatic load age-specific sex differences 75–78</td>
<td></td>
</tr>
<tr>
<td>health care utilization and gender differences 486, 487</td>
<td></td>
</tr>
<tr>
<td>insulin-like growth factor-1 effects 299</td>
<td></td>
</tr>
<tr>
<td>lesbian, gay, bisexual and transgender population 14</td>
<td></td>
</tr>
<tr>
<td>mortality female advantage 482, 483</td>
<td></td>
</tr>
<tr>
<td>prospects for study 487</td>
<td></td>
</tr>
<tr>
<td>Alcoholism</td>
<td></td>
</tr>
<tr>
<td>fetal alcohol spectrum disorders 39</td>
<td></td>
</tr>
<tr>
<td>stroke risks 135</td>
<td></td>
</tr>
<tr>
<td>treatment 201</td>
<td></td>
</tr>
<tr>
<td>Aldosterone</td>
<td></td>
</tr>
<tr>
<td>primary aldosteronism 324</td>
<td></td>
</tr>
<tr>
<td>secretion regulation 317</td>
<td></td>
</tr>
<tr>
<td>Allostatic load, see Stress</td>
<td></td>
</tr>
<tr>
<td>Alosetron, irritable bowel syndrome management 179</td>
<td></td>
</tr>
<tr>
<td>Alprostadil, erectile dysfunction management 451</td>
<td></td>
</tr>
<tr>
<td>Alteplase, sex differences in stroke treatment 140</td>
<td></td>
</tr>
<tr>
<td>Ambiguous genitalia</td>
<td></td>
</tr>
<tr>
<td>assisted reproductive technology risks 60</td>
<td></td>
</tr>
<tr>
<td>chromosomal disorders 57</td>
<td></td>
</tr>
<tr>
<td>congenital adrenal hyperplasia 40, 41, 57, 58</td>
<td></td>
</tr>
<tr>
<td>environmental factors 60, 61</td>
<td></td>
</tr>
<tr>
<td>genital tubercule anatomical aspects 61, 62</td>
<td></td>
</tr>
<tr>
<td>genitalia development 55, 56</td>
<td></td>
</tr>
<tr>
<td>gonad malignancy risks 64</td>
<td></td>
</tr>
<tr>
<td>hormonal failures 60</td>
<td></td>
</tr>
<tr>
<td>hormone therapy 63</td>
<td></td>
</tr>
<tr>
<td>maternal androgen sources 58, 59</td>
<td></td>
</tr>
<tr>
<td>micropenis outcomes 66</td>
<td></td>
</tr>
<tr>
<td>molecular biology 56</td>
<td></td>
</tr>
<tr>
<td>placental dysfunction 60</td>
<td></td>
</tr>
<tr>
<td>reproductive duct development 54</td>
<td></td>
</tr>
<tr>
<td>sex assignment 62</td>
<td></td>
</tr>
<tr>
<td>sex determination 38, 39, 52–54</td>
<td></td>
</tr>
<tr>
<td>sexual identity 62</td>
<td></td>
</tr>
<tr>
<td>surgery</td>
<td></td>
</tr>
<tr>
<td>feminization surgery 64</td>
<td></td>
</tr>
<tr>
<td>masculinization surgery 63</td>
<td></td>
</tr>
<tr>
<td>outcomes 65</td>
<td></td>
</tr>
<tr>
<td>phalloplasty 66</td>
<td></td>
</tr>
<tr>
<td>undervirilized males 59</td>
<td></td>
</tr>
<tr>
<td>uterine remnants 64, 65</td>
<td></td>
</tr>
<tr>
<td>Analgesia, see Pain</td>
<td></td>
</tr>
</tbody>
</table>
Androgen insensitivity syndrome (AIS) 40, 41, 56, 57
Androgen receptor (AR), mutations 56
Angina, see Coronary heart disease
Angiotensin-converting enzyme inhibitors
heart failure management 220
hypertension management, see
Hypertension
Angiotensin receptor blockers (ARBs)
heart failure management 220–222
hypertension management, see
Hypertension
Ankylosing spondylitis, see also
Spondyloarthritis
clinical features 367, 368
 genetics 370, 371
 pregnancy 375–377
 sex differences
 clinical expression 371, 372
 functional outcomes 373
 incidence 369, 370
Anterior cruciate ligament (ACL), sexual
 dimorphism in injury 361
Antidepressants, see specific drug classes
Antimüllerian hormone, see Müllerian
inhibiting substance
Arrhythmia
atrial fibrillation 232, 233
bradyarrhythmia 231
gender differences
 cardiac electrophysiology 229, 230
 treatment
catheter ablation 234
 implantable cardiac defibrillator 234
 pharmacotherapy 234
 prospects for study 234, 235
 sex hormone studies 230, 231
 stress mediation 231
 supraventricular tachyarrhythmias 232
ventricular arrhythmias 233
Arthritis, see Gout; Osteoarthritis; Rheumatoid
arthritis; Spondyloarthritis
Aspirin, sex differences in stroke prevention 141
Atrial fibrillation
gender differences 232, 233
stroke risks 134
Attention deficit hyperactivity disorder
(ADHD), fetal programming 45
Autism
clinical features 82, 83
epidemiology 83
male predominance mechanisms
 immunoreactive theory 89
müllerian inhibiting substance 89
parental manipulation of sex ratio 89
sex differences in symptomatology 89, 90
pathogenesis
 extreme male brain theory 83–85
testosterone role 85, 86
X-linked inheritance 86–88
Y chromosome role 88
prevalence 83
Basal metabolic rate (BMR), sex
differences 284, 285
Benign prostatic hyperplasia (BPH)
diagnosis 431
etiology and pathogenesis 429, 430
histology 253, 257
nuclear receptors 257, 258
overview 428, 429
progression 430
signaling pathways 260, 261
treatment
drugs 431, 432
minimally invasive treatment 432
surgery 432, 433
Benzylamine, sex differences in
metabolism 475
Beta-blockers
heart failure management 222–224
hypertension management, see
Hypertension
Bone
aging effects on mass 311, 312
diseases, see Osteoarthritis; Osteomalacia;
Osteoporosis; Paget's disease of bone;
Rheumatoid arthritis; Spondyloarthritis
estrogen regulation 311, 312
Bone mineral density (BMD), antiepileptic
drug studies 156
Botulinum toxin, overactive bladder
management 436
Bradyarrhythmia, see Arrhythmia
Brain, see also specific areas
fetal sex steroid exposure and physical,
cognitive, and behavioral outcomes 42, 43
sexual dimorphism 41, 42
Breakthrough, violence against women
reduction 120
Cancer
complexity
  cancer stem cells 247
epigenetics 247
gene mutations 246, 247
inflammation 247, 248
microRNAs 247
tissue environment 248
tumor cell heterogeneity 247
Warburg effect 248
gall bladder cancer and nuclear receptor signaling 262
incidence and gender differences
  female-predominant cancers 242, 243
  little or no difference between sexes 245
  male-predominant cancers 243–245
overview 238–240
specific cancers by sex 241, 242
tumor biology studies 248, 249
mortality and prognosis 240
thyroid cancer, sex differences 306
Vogel-Hanahan-Weinberg paradigm 245, 246
Y chromosome in risk 249
Cardiac arrhythmia, see Arrhythmia
Cardiovascular disease, see Coronary heart disease; Stroke
Carotid artery, stroke risks
  dissection 136
  stenosis 134, 135
Catechol-O-methyltransferase (COMT), sex differences in Parkinson's disease treatment with inhibitors 131
Cephadrine, sex differences in metabolism 475
Child marriage, see Violence against women
Chronic kidney disease (CKD)
  dialysis and sex differences
    access 462
    erythropoietin resistance 462
    mortality 459, 460
  end-stage renal disease progression 457, 458
  hypogonadism 460, 461
City of Joy, violence against women
  reduction 120
Clinical trials, inclusion of women
  Food and Drug Administration policies and practices 469, 470
  historical perspective 466, 467
  prospects 471
  rationale 467–469
Clomipramine, premature ejaculation
  management 454
Clopidogrel, sex differences in stroke prevention 141
Cluster headache, see Headache
Cognitive behavioral therapy (CBT), irritable bowel syndrome management 176, 180
Congenital adrenal hyperplasia (CAH)
  ambiguous genitalia 57, 58
  clinical features 318, 319
  epidemiology 318
  forms 319
  intrauterine testosterone effects 40, 41
Contraception, see Oral contraceptives
Coronary heart disease (CHD)
  delay in seeking care 196, 197
  diabetes, gender differences in risk 275–277
  diagnosis
    angiography 199
    exercise stress testing 198
    nuclear stress testing 198
    risk factor assessment models 197, 198
  differential diagnosis 197
  epidemiology 190–192
  erectile dysfunction comorbidity 448, 449
  fetal programming 43, 44
  hormone replacement therapy studies
    primary prevention 207–209
    recommendations 209, 210
    secondary prevention 209
  prospects for study 203, 204
  rehabilitation 202
  risk factors
    diabetes 194, 195
    diet 192, 193
    hypertension 194
    obesity 195
    sedentary lifestyle 193
    smoking 193, 194
    stress 195
  symptoms
    acute coronary syndrome 196, 197
    angina 196
    myocardial infarction 195, 196
  treatment
    acute coronary syndrome 201, 202
    alcoholism 201
    diabetes 201
Subject Index

guidelines 199
hypertension 200
myocardial infarction 201, 202
obesity 201
smoking cessation 201
statins 200
stress management 201
Cortisol, secretion regulation 317
Cushing's disease
epidemiology 300, 301
subclinical 323, 324
treatment 324
Cyclophosphamide, systemic lupus
erythematosus management 340
Dapoxetine, premature ejaculation
management 454
Dehydroepiandrosterone (DHEA)
androgen deficiency in women 319–322
synthesis 317
Dehydroepiandrosterone sulfate (DHEAS),
synthesis 317
Delayed ejaculation (DE)
definition 454
epidemiology 454, 455
pathophysiology 455
treatment 455
Dense breast
histology 253
pathology 260
signaling pathways 260, 261
Depression
antidepressants, see specific drug classes
epidemiology 93
integrated model 97
pathogenesis
  genetics 96
gonadal steroids 96, 97
  physiological dimorphisms 95
  psychosocial factors 95, 96
  postpartum depression, hormonal
  pathogenesis 96, 97
treatment 93–95
Desired drug reactions (DDRs), sex
differences 473, 474
Diabetes
coronary heart disease
management 201
risks 194, 195
fetal programming 43
gestational diabetes 280, 281
stroke risk factor 135, 136
type 1 disease
  clinical features 269, 270
  complications 270
diagnosis 270
epidemiology 268, 269
gender issues
  management of disease 270, 271
  pregnancy 271
  sex hormone concentrations 272
  pathophysiology 269
type 2 disease
  comorbidity 279, 280
diagnosis 274, 275
epidemiology 273, 274
macrovascular complications by
gender 275–277
microvascular complications 277, 278
reproduction effects 280
risk factors in relation to gender 275
treatment and prognosis, sex
disparities 278, 279
Dialysis, see Chronic kidney disease
Digoxin, heart failure management 224
Disorders of sex development, see Ambiguous
  genitalia
Distribution, sex differences for drugs 476
Diuretics 219
L-Dopa, sex differences in Parkinson's disease
treatment
Dutch Famine 43
Dyspareunia
  men 455
  women 442
Electrostimulation, overactive bladder
management 436
Elimination, sex differences for drugs 477
End-stage renal disease, see Chronic kidney
disease
Epigenetics, see Cancer; Fetal programming
Epilepsy
  antiepileptic drugs and gender differences
    adverse effects 153, 154
    bone health 156
    menopause 155
    pharmacokinetics 154, 155
    catamenial epilepsy 153
    mortality 152
    sex hormones and susceptibility 153
    Eplerenone, heart failure management 224
Epstein-Barr virus (EBV), multiple sclerosis risks 147

Erectile dysfunction (ED)
  epidemiology 447, 448
  hormonal factors 449, 450
  neurological factors 450
  pathophysiology 448
  psychological factors 450
  treatment 450, 451
  vascular factors 448, 449

Estrogen
  bone mass regulation 311, 312
  migraine role 158, 159
  multiple sclerosis protection 149
  Parkinson's disease neuroprotection 128, 129
  systemic lupus erythematosus mediation 337
  uric acid, response of serum level 382, 383

Estrogen receptor (ER)
  benign prostatic hyperplasia role 257
  ER-β
    immune system role 261, 262
    lymphoangioleiomyomatosis role 259, 260
    signaling 254
  immune disease modulation 261
  isoforms and proliferation effects 252
  knockout mice 253, 254, 261
  liver X receptor crosstalk 256

Female genital mutilation (FGM) 99, 100, 104, 108

Fetal alcohol spectrum disorders (FASD) 39

Fetal programming
  brain sexual dimorphism 41, 42
  exogenous effects on intrauterine environment 39, 40
  intelligence 46, 47
  maternal nutrition effects on adult diseases 43, 44
  maternal stress effects 44–46
  obstetrics implications 49, 50
  overview 37, 38
  predictive adaptive response 46
  sex steroid exposure and physical, cognitive, and behavioral outcomes 42, 43
  sexual orientation 47–48
  species survival strategy 48
  testosterone and intrauterine effects 40, 41
  twin studies 48

Fibromyalgia
  classification 164, 165
  gender differences 165–167
  overview 164
  pathophysiology 165, 166
  treatment 167

Finasteride, benign prostatic hyperplasia management 430, 431

Gall bladder cancer, nuclear receptor signaling 262

Genitalia, see Ambiguous genitalia; Female genital mutilation

Geriatrics, see Aging; Multimorbidity

Gestational diabetes, see Pregnancy

Gonadal dysgenesis, see Ambiguous genitalia

Gonadotropin-releasing hormone (GnRH), agonists for systemic lupus erythematosus management 340

Gout
  clinical features 383
  diagnosis 383
  epidemiology 380, 381
  pathogenesis
    hormone effects on serum urate 382, 383
    monosodium urate crystal-induced inflammation 383
    uric acid homeostasis 381, 383
  treatment 383

Growth hormone (GH)
  hypersecretion
    etiology 299
    prolactinoma 296
    physiology 298, 299

Headache, see also Migraine
  classification and causes 157
  cluster headache
    epidemiology 161
    gender effects 161
    migraine comorbidity 160, 161
    pathogenesis 161
  secondary headache 162
  tension-type headache and migraine comorbidity 160

Healthcare
  gender effects 14–16
  utilization by lesbian, gay, bisexual and transgender population 11, 12
### Subject Index

**Heart failure**
- definition 213
- diagnosis 217, 218
- epidemiology 213–215
- etiology 215, 216
- pathogenesis 217
- prognosis 216, 217
- treatment
  - exercise 226, 227
  - implantable cardiac defibrillator 225, 226
- pharmacotherapy
  - angiotensin-converting enzyme inhibitors 220
  - angiotensin receptor blockers 220–222
  - beta-blockers 222–224
  - digoxin 224
  - diuretics 219
  - eplerenone 224
  - overview 218, 219
  - spironolactone 224

**Hermaphroditism** 57

**Hirsutism**
- etiology 322
- treatment 322, 323

**Historical perspective**
- gender-specific medicine 5–7
- gender thought evolution 1–4

**Hormone replacement therapy**
- coronary heart disease studies
  - primary prevention 207–209
  - recommendations 209, 210
  - secondary prevention 209
- dense breast 260
- rheumatoid arthritis management 355
- stroke risks 137
- systemic lupus erythematosus management 340, 341

**Human immunodeficiency virus (HIV)**
- epidemiology
  - female susceptibility 389, 390
  - frequency of infection 388, 389
  - sexual minority susceptibility 390
  - morbidity 390
- prevention and health policy 394
- reproduction 393, 394
- treatment and gender considerations
  - adverse effects 392
  - drug-drug interactions 393
  - health care access 391
- pharmacokinetics 391, 392
- tuberculosis comorbidity 415
- viral load differences by gender 390

**Hypercalcemia**
- causes 308, 309
- lithium induction 310

**Hyperparathyroidism, see Parathyroid hormone**

**Hyperprolactinemia**
- diagnosis 295, 296, 298
- erectile dysfunction comorbidity 449, 450
- etiology 297
- prolactinoma 296

**Hypertension**
- coronary heart disease
  - management 200
  - risks 194
- endocrine hypertension 325
- stroke
  - management in prevention 142
  - risks 134

**Hyperthyroidism**
- subclinical hyperthyroidism 302
- thyrotoxicosis 301, 302

**Hypnotherapy, irritable bowel syndrome**
- management 176, 180

**Hypoactive sexual desire, see Sexual dysfunction**

**Hypothyroidism**
- subclinical hypothyroidism 303, 305, 306
- treatment 304, 305

**Implantable cardiac defibrillator (ICD)**
- heart failure management 225, 226
- sudden cardiac death prevention 234

**Inflammatory bowel disease, arthritis** 369

**Insulin-like growth factor-1 (IGF-1)**
- aging effects 299
- growth hormone hypersecretion
  - effects 299, 300
- physiology 298

**Intelligence, fetal programming** 46, 47

**International Rescue Committee, violence against women reduction** 120, 121

**Intersex, see Ambiguous genitalia; Lesbian, gay, bisexual and transgender**
Irritable bowel syndrome (IBS)
   comorbidity 176
   diagnosis 174
   differential diagnosis 176, 177
   epidemiology 173
   menstrual cycle and hormonal effects 175
   postinfectious disease 175
   prospects for study 181
   treatment
      cognitive behavioral therapy 176, 180
      hypnotherapy 176, 180
      lifestyle changes 177
      mindfulness-based stress reduction 180
      pain management
         antispasmodics 179
         tricyclic antidepressants 179
         patient-physician relationship 181
      pharmacotherapy for syndrome with
         constipation
            lubiprostone 178
            tegaserod 178
      pharmacotherapy for syndrome with
         diarrhea
            alosetron 179
            loperamide 178, 179
            probiotics 180
            rifaximin 179, 180
            types 174, 175
   knockout mice 253, 254, 257, 258
   signaling 256
   Long QT syndrome (LQTS)
      gender differences 233
      sex hormone studies 231
   Loperamide, irritable bowel syndrome
      management 178, 179
   Lower urinary tract symptoms (LUTS), see also
      Benign prostatic hyperplasia
      diagnosis 431
      etiology 433
      overactive bladder 433–436
      overview 428, 429
      prevalence 429
   Lubiprostone, irritable bowel syndrome
      management 178
   Lymphoangioleiomyomatosis (LAM)
      histology 253, 258, 259
      nuclear receptors 259, 260
      signaling pathways 260, 261
   Malaria
      diagnosis 397, 398
      epidemiology 396
      gendering of research 403
      health care access and treatment
         compliance 400
      pathogenesis 397
      prevention 400–403
      risk factors 399, 400
      symptoms 397
      transmission 396
      treatment 398, 399
   Measles
      epidemiology 405, 406
      eradication 406, 407, 412
      prospects for study 412
      transmission model of severe disease 407–410
      vaccination and sex differences in
         response 410–412
   Menopause
      epilepsy studies 155
      hormone therapy, see Hormone
         replacement therapy
   Menstrual cycle
      migraine triggering 158, 159
      Parkinson’s disease effects 129
   Metabolism, sex differences for drugs 476
   Methotrexate, rheumatoid arthritis
      management 355

Kaposi’s sarcoma (KS), human immunodeficiency virus outcomes by gender 390
Klinefelter syndrome 59, 88, 338
Leiomyoma, histology 253
Lesbian, gay, bisexual and transgender (LGBT), see also Transsexualism
   aging 14
   definition 10
   fetal programming of sexual
      orientation 47–49
   human immunodeficiency virus
      susceptibility 390
   morbidity 13, 14
   resource allocation, empowerment and equity 14–16
Libido, see Sexual dysfunction
Life cycle model, stress 71, 72
Lithium, hypercalcemia induction 310
Liver X receptor (LXR)
   benign prostatic hyperplasia role 257, 258
   estrogen receptor crosstalk 256
   knockout mice 253, 254, 257, 258
   signaling 256
   Long QT syndrome (LQTS)
      gender differences 233
      sex hormone studies 231
   Loperamide, irritable bowel syndrome
      management 178, 179
   Lower urinary tract symptoms (LUTS), see also
      Benign prostatic hyperplasia
      diagnosis 431
      etiology 433
      overactive bladder 433–436
      overview 428, 429
      prevalence 429
   Lubiprostone, irritable bowel syndrome
      management 178
   Lymphoangioleiomyomatosis (LAM)
      histology 253, 258, 259
      nuclear receptors 259, 260
      signaling pathways 260, 261
   Malaria
      diagnosis 397, 398
      epidemiology 396
      gendering of research 403
      health care access and treatment
         compliance 400
      pathogenesis 397
      prevention 400–403
      risk factors 399, 400
      symptoms 397
      transmission 396
      treatment 398, 399
   Measles
      epidemiology 405, 406
      eradication 406, 407, 412
      prospects for study 412
      transmission model of severe disease 407–410
      vaccination and sex differences in
         response 410–412
   Menopause
      epilepsy studies 155
      hormone therapy, see Hormone
         replacement therapy
   Menstrual cycle
      migraine triggering 158, 159
      Parkinson’s disease effects 129
   Metabolism, sex differences for drugs 476
   Methotrexate, rheumatoid arthritis
      management 355
Micropenis, see Ambiguous genitalia
Migraine
    comorbidity
        cluster headache 160, 161
tension-type headache 160
epidemiology 158
gender effects 158
sex hormone studies 158, 159
stroke risks 137
treatment in women 159, 160
Mindfulness-based stress reduction, irritable bowel syndrome management 180
Monoamine oxidase inhibitors (MAOIs)
    gene polymorphisms in depression 96
    sex differences 94
Morbidity, see also Multimorbidity
    female disadvantage 483–486
    lesbian, gay, bisexual and transgender population 13, 14
    mortality paradox 12, 13, 482–486
Morphine, sex differences in response 183–185
Mortality, see also specific diseases
    morbidity paradox 12, 13
    female advantage 482, 483
    transsexualism 333
Müllerian inhibiting substance (MIS)
    ambiguous genitalia 60
    autism role 89
    sex determination 54
Multimorbidity
    consequences 491
    definition 489, 490
    gender differences 491–493
    prevalence 490
    prospects for study 493
    risk factors 490, 491
Multiple endocrine neoplasia type 1 (MEN1),
gender differences 301
Multiple sclerosis (MS)
    clinical features 144, 145
    epidemiology 143
    estrogen protection 149
    gene-environment interactions 147, 148
    genetics 145, 146
    pathogenesis 144
    pregnancy 149
    risk factors
        environmental factors 146, 147
        female predominance 148
        fertility rates in parents 149, 150
        treatment 150, 151
Myocardial infarction, see Coronary heart disease
Nicotine, see Smoking
Obesity
    body composition 284, 285
    body shape 283, 284
    comorbidity, females 288
    coronary heart disease management 201
    risks 195
    fetal programming 44
    geographic distribution 285, 286
    osteoarthritis risk 362–364
    primary care, gender differences 287, 288
    secular trends in body weight 286, 287
    stroke risks 135
    treatment, gender differences 288, 289
Obstructive sleep apnea, stroke risks 136
Olanzapine, sex differences in pharmacokinetics 468
Ondansetron, sex differences in pharmacokinetics 468
Oral contraceptives
    spondyloarthritis effects 375
    stroke risks 137
    systemic lupus erythematosus management 339, 340
Osteoarthritis, sexual dimorphism
    biomarkers of connective tissue activity 360
    joint conformation 359, 360
    pain, functioning, and injury 360
    pathogenesis
        obesity 362–364
        sex hormones 364, 365
    prevalence 358, 359
    treatment outcomes 365
Osteomalacia, vitamin D deficiency 310, 311
Osteoporosis
    causes 314
    clinical features 313
    diagnosis 312, 313
    fracture incidence 314
    pathology 312–315
    seronegative spondyloarthritis 372, 373
    treatment 315
Overactive bladder
    epidemiology 433, 434
    etiology 434
    treatment 434–436
Oxybutynin, overactive bladder management 435

Paget’s disease of bone
clinical presentation 315, 316
pathogenesis 316

Pain
analgesia response sex differences
morphine 183–185
prospects for study 186
sex hormone studies 186
descending modulatory pathway 184, 187

Parathyroid hormone (PTH)
calcium homeostasis 308, 309
primary hyperparathyroidism 309

Parkinson’s disease (PD)
clinical features
motor symptoms 127
nonmotor symptoms 127, 128
epidemiology 126
estrogen neuroprotection 128, 129
etiology 128
menstruation effects 129
pharmacotherapy outcomes 130, 131
pregnancy studies 130
prospects for study 131, 132
surgery outcomes 131

Periaqueductal gray (PAG), sexual dimorphism 184–187

Pharmacodynamics, sex differences 477, 478
Pharmacokinetics, sex differences 474–477

Pheochromocytoma, features and diagnosis 324

Phosphodiesterase type 5 (PDE5), inhibitors for erectile dysfunction management 449–451

Pioglitazone, fracture risk 469

Pituitary
anatomy 292
diseases, see Cushing’s disease; Growth hormone; Hyperprolactinemia; Multiple endocrine neoplasia type 1
hormones 292, 293
nonfunctioning adenoma 300
tumors 293–295

Polycystic ovarian disease (PCOD), clinical features 288

Postpartum depression (PPD), hormonal pathogenesis 96, 97

Predictive adaptive response (PAR) 46

Pregnancy, see also Fetal programming;
Postpartum depression
antiepileptic drug pharmacokinetics 154, 155
diabetes
gestational diabetes 280, 281
type I 271
type II 280
malaria management 398, 399
multiple sclerosis 149
Parkinson’s disease studies 130
spondyloarthritis
disease activity effects 375, 376
outcomes 377
stroke risks 137, 138
systemic lupus erythematosus
antiphospholipid syndrome 345, 346
complications 341, 342
disease activity 342, 343
drug safety 343–345
fertility effects 341
neonatal lupus 346, 347

Premature ejaculation (PE)
definition 452
drug induction 453
endocrine factors 453
epidemiology 452
 genetics 453
pathophysiology 452
psychological factors 453, 454
treatment 454
urological factors 453

Probiotics, irritable bowel syndrome management 180

Psoriatic arthritis, see also Spondyloarthritis
clinical features 368, 369
oral contraceptive effects 375
sex differences in incidence 370

Rape, see Violence against women
Reactive arthritis, clinical features 369
Reiter’s syndrome, see Reactive arthritis
Rheumatoid arthritis (RA)
course and prognosis 350–353
diagnosis
acute-phase reactants 354
autoantibodies 354
classification criteria 353, 354
disease activity measurement 350, 351
epidemiology 350
etiology 349
prospects for study 356

treatment
  hormone replacement therapy 355
  methotrexate 355
  overview 349, 350, 355
  response 355
Rifampicin, sex differences in metabolism 475
Rifaximin, irritable bowel syndrome
  management 179, 180
Rosiglitazone, fracture risk 469
Selective serotonin reuptake inhibitors (SSRIs)
  premature ejaculation management 454
  sex differences 94
Serotonin transporter (SERT), fibromyalgia
  studies 166
Sex, versus gender 5–7
Sex determination, biology 38, 39, 52–54
Sex hormone-binding globulin (SHBG),
  diabetes type I levels 271
Sex ratio at birth (SRB)
  Caribbean 28
  Caucus region 26
  China 18–20, 23
  demographic effect 29–31
  India 25–27
  Latin America 28
  Middle East 27
  social implications 32, 33
  South Korea 23, 24
  United Kingdom 28, 29
  United States 28, 29
  Vietnam 24, 25
Sex-selective abortion, see also Sex ratio at
  birth
  China demographics 18–20
  demographic effect 29–31
  parity-specific imbalance and
drivers 20–25
  prospects 34
  social implications 32, 33
Sexual dysfunction
  men
    delayed ejaculation
      definition 454
      epidemiology 454, 455
      pathophysiology 455
      treatment 455
    dyspareunia 455
    erectile dysfunction
      epidemiology 447, 448
  hormonal factors 449, 450
  neurological factors 450
  pathophysiology 448
  psychological factors 450
  treatment 450, 451
  vascular factors 448, 449
  hypoactive sexual desire
    definition 451
    epidemiology 451
    pathophysiology 451, 452
    treatment 452
    overview 446, 447
  premature ejaculation
    definition 452
    drug induction 453
    endocrine factors 453
    epidemiology 452
    genetics 453
    pathophysiology 452
    psychological factors 453, 454
    treatment 454
    urological factors 453
  women
    classification of dysfunction 439, 440
    concurrence of types 443, 444
    dyspareunia 442
    etiology 440
    overview 438, 439
    persistent genital arousal disorder 441,
442
    prevalence 442, 443
    risk factors 444
    sexual arousal dysfunction 441
    sexual interest and desire 441
    vaginismus 442
Sexual orientation, see Lesbian, gay, bisexual
  and transgender
Sinus thrombosis, stroke risks 138
Smoking
  cessation 201
  coronary heart disease risks 193, 194
  fetal effects of nicotine 39, 40
  multiple sclerosis risks 147
  stroke risks 135
Spironolactone, heart failure management 224
Spondyloarthritis
  ankylosing spondylitis 367, 368
  clinical expression 371, 372
  functional outcomes 373
  genetics 370, 371
  gonadal hormone levels 374, 375
inflammatory bowel disease arthritis 369
mortality 373, 374
pregnancy 375–377
psoriatic arthritis 368, 369
radiographic changes 372
reactive arthritis 369
seronegative disease
  exogenous hormone effects 375
  osteoporosis 372, 373
sex ratio 369, 370
treatment response 374
SRY gene
  autism role 88
  sex determination 38, 53, 57
Statins
coronary heart disease management 200
sex differences in stroke prevention 141
Stress
  allostatic load
    age-specific sex differences 75–78
    evolution of sex and gender
differences 78
  gender differences 78
  index 73–75
  prospects for study 80
  reduction 79
arrhythmias and mediation 231
cancer risks 249
clinical aspects
  life cycle model 71, 72
  neurological regulation and allostatic
load 71
coronary heart disease
  management 201
  risks 195
measurement 70, 71
mindfulness-based stress reduction and
irritable bowel syndrome
  management 180
prenatal stress and fetal
programming 44–46
temporal cascade of allostatic load
  mediators 73
treatment
  pharmacotherapy 79, 80
  resilience fostering 79
Stress testing, see Coronary heart disease
Stroke
  clinical evaluation 139, 140
  clinical presentation 138, 139
  definition 133
diagnosis 139
epidemiology 133, 134
prevention
  antiplatelet agents 141
  hypertension drugs 142
  statins 141
  vitamin K antagonists 141
risk factors
  alcoholism 135
  atrial fibrillation 134
  carotid dissection 136
  carotid stenosis 134, 135
  diabetes 135, 136
  hormone replacement therapy 137
  hypertension 134
  migraine 137
  obesity 135
  obstructive sleep apnea 136
  oral contraceptives 137
  pregnancy 137, 138
  sedentary lifestyle 135
  sinus thrombosis 138
  smoking 135
  vertebral artery dissection 136
subarachnoid hemorrhage 138
thrombolytic therapy 140
transient ischemic attack and risks 133
Subarachnoid hemorrhage, see Stroke
Sudden cardiac death (SCD), gender
differences 233
Supraventricular tachyarrhythmias, see
Arrhythmia
Systemic lupus erythematosus (SLE)
  clinical features 338, 339
  diagnosis 339
  epidemiology 336, 337
  pathogenesis 336–338
  pregnancy
    antiphospholipid syndrome 345, 346
    complications 341, 342
    disease activity 342, 343
    drug safety 343–345
    fertility effects 341
    neonatal lupus 346, 347
  treatment
    cyclophosphamide 340
gonadotropin-releasing hormone
  agonists 340
  hormone replacement therapy 340, 341
  oral contraceptives 339, 340
tamoxifen 337, 338
Tamoxifen, systemic lupus erythematosus management 337, 338
Tegasterod, irritable bowel syndrome management 178
Temporomandibular joint disorder (TMJD) clinical features 169–171
diagnosis 171
epidemiology 169
gender differences 170, 171
prospects for study 171
treatment 171
Tension-type headache, see Headache
Testis-determining factor (TDF) 57
Testosterone
autism role 85, 86
deficiency in women 319–322
erectile dysfunction levels and therapy 449
intrauterine effects 40–43
maternal androgen sources 58, 59
Thuthuzela Care Centre (TCC), violence against women reduction 121
Thyroid cancer, sex differences 306
Thyroid hormone, see Hyperthyroidism; Hypothyroidism
Tobacco, see Smoking
Tolterodine tartrate, overactive bladder management 435
Torsades de pointes, drug induction 468, 469
Total knee replacement (TKR), sexual dimorphism in outcomes 365
Transforming growth factor-β (TGF-β), signaling in gonadal hormone regulation of stromal-epithelial growth 254–256
Transsexualism clinical features 328, 329
diagnosis 328, 330, 331
epidemiology 329
etiology 329, 330
mortality 333
overview 327, 328
treatment
female-to-male transsexualism 331
male-to-female transsexualism 331, 332
outcomes 333
sex reassignment surgery 332, 333
Transurethral microwave thermotherapy (TUMT), benign prostatic hyperplasia management 432
Tricyclic antidepressants (TCAs) irritable bowel syndrome management 179
sex differences 94
Trivers-Willard effect (TWE) 48
Tuberculosis, gender dynamics
active versus passive case detection 416–418
course of infection 418
diagnosis 418, 419
epidemiology 415, 418
human immunodeficiency virus comorbidity 415
importance of study 414, 415
regional variation 416
social consequences 422, 423
symptoms 149–422
treatment adherence 423
Turner syndrome 57
U.N. to End Violence against Women 121
United Nations Trust Fund, violence against women reduction 119
Uric acid, see Gout
Vaginismus 442
V-Day, violence against women reduction 119, 120
Ventricular arrhythmias, see Arrhythmia
Verapamil, sex differences in metabolism 475
Vertebral artery dissection, stroke risks 136
Violence against women
causes
armed conflict 108
discrimination against women 106
legal system 107
consequences
health consequences 106
poverty 105
definition 103
East Africa
access to services for victims 115
causes 111, 112
economic pillar 113
forms of violence 109–111
mitigation of violence 118, 119
overview 108, 109
political pillar 113
stranger violence 110
male perpetrators 102, 103
neurohormonal mechanisms for regulated aggression 101, 102
overview 99–101
reduction
empowerment 116, 117
<table>
<thead>
<tr>
<th>Laws, policies, and budgets</th>
<th>117, 118</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local and national actions</td>
<td>116</td>
</tr>
<tr>
<td>Multispectral partnerships</td>
<td>118</td>
</tr>
<tr>
<td>Programs and initiatives</td>
<td>119–124</td>
</tr>
<tr>
<td>Social norm changing</td>
<td>117</td>
</tr>
<tr>
<td>Unconventional ally enlistment</td>
<td>118</td>
</tr>
<tr>
<td>Types</td>
<td></td>
</tr>
<tr>
<td>Armed conflict</td>
<td>105</td>
</tr>
<tr>
<td>Child marriage</td>
<td>104, 105</td>
</tr>
<tr>
<td>Female genital mutilation</td>
<td>104</td>
</tr>
<tr>
<td>Intimate partner perpetration</td>
<td>104</td>
</tr>
<tr>
<td>Rape</td>
<td>104</td>
</tr>
<tr>
<td>Victim rights</td>
<td>113–115</td>
</tr>
<tr>
<td>Vitamin D</td>
<td></td>
</tr>
<tr>
<td>Multiple sclerosis studies</td>
<td>146, 147</td>
</tr>
<tr>
<td>Osteomalacia and deficiency</td>
<td>310, 311</td>
</tr>
<tr>
<td>Warburg effect, cancer</td>
<td>248</td>
</tr>
<tr>
<td>Warfarin, sex differences in stroke prevention</td>
<td>141</td>
</tr>
<tr>
<td>Women's Health and Action Research Center, violence against women reduction</td>
<td>122</td>
</tr>
</tbody>
</table>